Who is sponsoring NCT02298387?

NCT02298387 is sponsored by OncoMed Pharmaceuticals, Inc..

What drugs are being tested in NCT02298387?

Interventions in NCT02298387: OMP-305B83.

What condition does NCT02298387 study?

NCT02298387 studies Advanced Solid Tumor Malignancies.

Is NCT02298387 still recruiting?

NCT02298387 is currently completed. Last updated 11 August 2020.

Last reviewed 2020-08-11 · How we verify

NCT02298387

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase 1 Study of OMP-305B83 in Subjects With Solid Tumors

Completed Phase 1 Last updated 11 August 2020

What this trial tests

Phase 1 trial testing OMP-305B83 in Advanced Solid Tumor Malignancies in 71 participants. Completed in 8 September 2017.

Timeline

22 December 2014

Primary endpoint
23 May 2017

8 September 2017

Quick facts

Lead sponsor	OncoMed Pharmaceuticals, Inc.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	71
Start date	22 December 2014
Primary completion	23 May 2017
Estimated completion	8 September 2017
Sites	4 locations across United States

Drugs / interventions tested

OMP-305B83 — full drug profile →

Conditions studied

Advanced Solid Tumor Malignancies — all drugs for Advanced Solid Tumor Malignancies →

Sponsor

OncoMed Pharmaceuticals, Inc. — full company profile →

Who can join

21 and older, any sex, with Advanced Solid Tumor Malignancies. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an open-label Phase 1 dose escalation and expansion study of OMP-305B83 in subjects with previously treated solid tumors. Study includes a dose escalation phase and expansion phase. Subjects will be assessed for safety, immunogenicity, pharmacokinetics, biomarkers, and efficacy.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Bispecific antibodies and their applications.
Fan G, Wang Z, Hao M, Li J. · · 2015 · cited 200× · PMID 26692321 · DOI 10.1186/s13045-015-0227-0
Current progress in innovative engineered antibodies.
Strohl WR. · · 2018 · cited 169× · PMID 28822103 · DOI 10.1007/s13238-017-0457-8
Precision medicine for human cancers with Notch signaling dysregulation (Review).
Katoh M, Katoh M. · · 2020 · cited 159× · PMID 31894255 · DOI 10.3892/ijmm.2019.4418
Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeutics.
Runcie K, Budman DR, John V, Seetharamu N. · · 2018 · cited 120× · PMID 30249178 · DOI 10.1186/s10020-018-0051-4
Biology drives the discovery of bispecific antibodies as innovative therapeutics.
Nie S, Wang Z, Moscoso-Castro M, D'Souza P, et al · · 2020 · cited 79× · PMID 33928225 · DOI 10.1093/abt/tbaa003
Principles and Current Clinical Landscape of Multispecific Antibodies against Cancer.
Elshiaty M, Schindler H, Christopoulos P. · · 2021 · cited 71× · PMID 34073188 · DOI 10.3390/ijms22115632
Recent advances and challenges of bispecific antibodies in solid tumors.
Wu Y, Yi M, Zhu S, Wang H, et al · · 2021 · cited 64× · PMID 34922633 · DOI 10.1186/s40164-021-00250-1
Therapeutic Targeting of Notch Signaling: From Cancer to Inflammatory Disorders.
Allen F, Maillard I. · · 2021 · cited 62× · PMID 34124039 · DOI 10.3389/fcell.2021.649205

Verify or expand the search:

Other recruiting trials for Advanced Solid Tumor Malignancies

Currently open trials in the same condition.

NCT06927297 — Phase I Study of the Safety, Tolerability, and Efficacy of an Engineered Mitochondrial Vaccine in Advanced Solid Tumors · Phase 1 · recruiting
NCT06649708 — HX044,FIH Study in Patients with Advanced Solid Tumor Malignancies · Phase 1, PHASE2 · recruiting

Other OncoMed Pharmaceuticals, Inc. trials

Trials by the same sponsor.

NCT03295942 — A Study of OMP-336B11 in Subjects With Locally Advanced or Metastatic Tumors · Phase 1 · terminated
NCT03119428 — A Study of OMP-313M32 in Subjects With Locally Advanced or Metastatic Solid Tumors · Phase 1 · terminated
NCT02482441 — A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10 · Phase 1 · completed
NCT01952249 — A Study of Demcizumab Plus Paclitaxel in Subjects With Platinum Resistant Ovarian · Phase 1 · terminated
NCT01859741 — A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Etoposide and Platinum Therapy · Phase 1, PHASE2 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02298387 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by OncoMed Pharmaceuticals, Inc.
Last refreshed: 11 August 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02298387.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing